{"entity":{"id":"nct03744715","kind":"trial","name":"A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib","aka":[],"tldr":"A phase 2 trial of Poziotinib in Breast cancer, run by Spectrum Pharmaceuticals, Inc, recorded as terminated on the registry.","summary":"A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib is a phase 2 interventional study registered as NCT03744715 by Spectrum Pharmaceuticals, Inc, with 7 participants recorded, started 2018-10-11 and due to reach its primary completion in 2023-03-03. Interventions recorded: Poziotinib. Conditions recorded: NSCLC, Breast Cancer.\n\nLinked to the drug Poziotinib because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT03744715","url":"https://clinicaltrials.gov/study/NCT03744715"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["poziotinib"],"companies":["spectrum-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03744715","phase":"2","setting":"An Open-Label Extension Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib","sponsor":"Spectrum Pharmaceuticals, Inc","enrolled":7,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03744715/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"poziotinib","kind":"drug","name":"Poziotinib","route":"/drugs/poziotinib/"}],"company":[{"id":"spectrum-pharmaceuticals","kind":"company","name":"Spectrum Pharmaceuticals","route":"/companies/spectrum-pharmaceuticals/"}]}}